John Wilkerson is a Washington correspondent at RamaOnHealthcare. He focuses on the intersection of health and wellness, healthcare technology, and pharmaceuticals, covering topics such as pharmaceutical manufacturing, public health, and healthcare administration. His insights and analyses have been featured in STAT News and Daily Republic.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
John Wilkerson’s coverage predominantly focuses on healthcare and pharmaceuticals, with a strong emphasis on government announcements and legal policy regulations. Given this focus, he would likely be interested in receiving pitches from experts who can provide insights into the implications of new policies or regulatory changes within the healthcare and pharmaceutical sectors.
Given his interest in specific government actions related to drug pricing, FDA decisions, Medicare policies, and drug shortages, professionals with expertise in these areas may find success reaching out for commentary or analysis.
Wilkerson's US-based focus should be considered when pitching relevant stories or expert opinions tied to developments within the American healthcare system.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Democrats are focusing on health care affordability to draw a contrast with the GOP ahead of the midterms
You're reading the web edition of D.C. Diagnosis, STAT's twice-weekly newsletter about the politics and policy of health and medicine.
RFK Jr. adviser Calley Means and Kennedy's son Finn attended the Enhanced Games, the pro-doping athletic competition and biohacking extravaganza
The public is about to get its first look at the prices of drugs launched since President Trump struck his most-favored-nation deals with 17 drugmakers.
You're reading the web edition of D.C. Diagnosis, STAT's twice-weekly newsletter about the politics and policy of health and medicine.
By: Tara Bannow, John Wilkerson
States and advocates are closely monitoring the policies WASHINGTON — The Trump administration on Monday published a highly anticipated
Plus a buried alcohol study gets published, and a Biosecure update.
You're reading the web edition of D.C. Diagnosis, STAT's twice-weekly newsletter about the politics and policy of health and medicine.
By: John Wilkerson
Trump administration revisits policy to plug Medicare drug price negotiation loophole.
By: John Wilkerson
After July 1, Medicare will offer GLP-1 weight-loss drugs for $50. It's supposed to be temporary, but chances are it won't be.
